Form 4: Amarin COO's Equity Transactions and Vesting Schedule

Amarin's EVP and COO, David Paul Keenan, reported recent equity transactions including RSU vesting, tax-related share dispositions, and new equity grants.

Summary

• David Paul Keenan, EVP, Chief Operating Officer of Amarin Corp PLC, reported transactions related to his equity holdings.
• On January 31, 2026, 2,246 American Depositary Shares (ADS) vested from a Restricted Stock Unit (RSU) grant made on February 21, 2023.
• Also on January 31, 2026, 1,933 ADS vested from an RSU grant made on February 1, 2024.
• The company withheld 1,173 ADS at a price of $15.42 for tax liability incident to the vesting of the 2023 RSU grant.
• The company also withheld 1,010 ADS at a price of $15.42 for tax liability incident to the vesting of the 2024 RSU grant.
• Following these transactions, Mr. Keenan beneficially owned 10,785 ADS from the first set of transactions and 11,708 ADS from the second set of transactions.
• On February 1, 2026, Mr. Keenan was granted 8,013 new RSUs under the Amarin Corporation plc 2020 Stock Incentive Plan.
• On February 1, 2026, Mr. Keenan was also granted an option to purchase 30,060 ADSs under the same plan.
• Effective April 11, 2025, Amarin implemented an ADS Ratio Change where one ADS now represents twenty Ordinary Shares, with proportionate adjustments made to outstanding equity awards.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting ongoing executive compensation and alignment of interests, with new equity grants indicating continued commitment to the company's performance.

Positives

• New grants of 8,013 Restricted Stock Units (RSUs) and an option to purchase 30,060 American Depositary Shares (ADS) on February 1, 2026, indicate continued executive incentive and alignment with shareholder interests.
• The vesting of previously granted RSUs represents a realization of compensation for the executive.

Negatives

• A total of 2,183 American Depositary Shares (ADS) were disposed of by the Issuer for tax withholding purposes, reducing the executive's direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive equity grants and vesting, along with associated tax withholdings, are standard compensation practices in the pharmaceutical industry. These mechanisms are designed to align management incentives with long-term shareholder value creation, a common approach across publicly traded companies.

Stakeholder Impact

• Shareholders: The grants of new equity awards align the executive's financial interests with those of shareholders, potentially fostering long-term value creation.
• Employees (Executive): The executive receives compensation through the vesting of RSUs and new equity grants, which are part of their overall compensation package.

Next Steps

• Future vesting installments for the 2024 RSU grant on January 31, 2027.
• Future vesting installments for the 2026 RSU grant on January 31, 2027, January 31, 2028, and January 31, 2029.
• Stock options granted on February 1, 2026, will vest over three years, with 33% vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 8 calendar quarters.

Key Dates

Recommendation

The filing details routine executive compensation activities, including RSU vesting and new equity grants. These transactions are standard and do not provide new fundamental information to warrant a change in investment thesis. The grants align management incentives with shareholder value, supporting a 'hold' position for existing investors.

Keywords

Amarin, AMRN, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Equity Grant, Vesting